

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Martin F. Stefanic, et al.) Art Unit: 1614
Serial No.: 10/830,147) Examiner: James D. ANDERSON
Confirmation No.: 7845
Filed: April 22, 2004
For: COMBINATIONS FOR THE TREATMENT OF DISEASES
INVOLVING CELL PROLIFERATION, MIGRATION OR
APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS
Docket No.: 01-1464

Via EFS Web
Commissioner for Patents
Alexandria, VA 22313-1450

PETITION UNDER 37 CFR 1.136(a) FOR EXTENSION OF TIME

Sir:

It is hereby requested that the time for responding to the Action mailed on December 18, 2007, be extended pursuant to 37 CFR 1.136(a) for three (3) months, to maintain the pendency of the above-captioned application until June 18, 2008.

The fee set in 37 CFR 1.17 for this extension of time is \$ 1,050.00. The Commissioner is hereby authorized to charge this and any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955.

Respectfully submitted,

/Mary-Ellen M. Devlin/
Mary-Ellen M. Devlin
Attorney for Applicant(s)
Reg. No. 27,928

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4866
Fax: (203) 798-4408

Date: June 17, 2008